India · Delayed Price · Currency is INR Concord Drugs Statistics
Total Valuation
Concord Drugs has a market cap or net worth of INR 620.50 million. The enterprise value is 810.68 million.
| Market Cap | 620.50M |
| Enterprise Value | 810.68M |
Important Dates
The last earnings date was Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Concord Drugs has 10.00 million shares outstanding. The number of shares has increased by 0.53% in one year.
| Current Share Class | 10.00M |
| Shares Outstanding | 10.00M |
| Shares Change (YoY) | +0.53% |
| Shares Change (QoQ) | +0.86% |
| Owned by Insiders (%) | 84.14% |
| Owned by Institutions (%) | n/a |
| Float | 1.59M |
Valuation Ratios
The trailing PE ratio is 146.40.
| PE Ratio | 146.40 |
| Forward PE | n/a |
| PS Ratio | 1.32 |
| PB Ratio | 1.82 |
| P/TBV Ratio | 1.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 190.03 |
| EV / Sales | 1.72 |
| EV / EBITDA | 19.04 |
| EV / EBIT | 28.36 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.56 |
| Debt / EBITDA | 4.52 |
| Debt / FCF | n/a |
| Interest Coverage | 1.38 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 3.41% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 2.55M |
| Profits Per Employee | 23,059 |
| Employee Count | 185 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Concord Drugs has paid 3.82 million in taxes.
| Income Tax | 3.82M |
| Effective Tax Rate | 47.26% |
Stock Price Statistics
The stock price has increased by +71.17% in the last 52 weeks. The beta is 0.45, so Concord Drugs's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +71.17% |
| 50-Day Moving Average | 52.34 |
| 200-Day Moving Average | 38.53 |
| Relative Strength Index (RSI) | 70.20 |
| Average Volume (20 Days) | 8,058 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Drugs had revenue of INR 471.58 million and earned 4.27 million in profits. Earnings per share was 0.42.
| Revenue | 471.58M |
| Gross Profit | 95.31M |
| Operating Income | 28.58M |
| Pretax Income | 8.09M |
| Net Income | 4.27M |
| EBITDA | 42.58M |
| EBIT | 28.58M |
| Earnings Per Share (EPS) | 0.42 |
Balance Sheet
The company has 2.25 million in cash and 192.44 million in debt, giving a net cash position of -190.18 million or -19.02 per share.
| Cash & Cash Equivalents | 2.25M |
| Total Debt | 192.44M |
| Net Cash | -190.18M |
| Net Cash Per Share | -19.02 |
| Equity (Book Value) | 341.14M |
| Book Value Per Share | 35.08 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 20.21%, with operating and profit margins of 6.06% and 0.90%.
| Gross Margin | 20.21% |
| Operating Margin | 6.06% |
| Pretax Margin | 1.72% |
| Profit Margin | 0.90% |
| EBITDA Margin | 9.03% |
| EBIT Margin | 6.06% |
| FCF Margin | n/a |
Dividends & Yields
Concord Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.53% |
| Shareholder Yield | -0.53% |
| Earnings Yield | 0.69% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |